Sugi Predict

Sugi Predict / Compounds / SCHEMBL484585

SCHEMBL484585

SCHEMBL484585

CC(C)(C)OC(=O)N1CCC2(CCNC2)CC1

nearest known ligand 0.55

Predicted protein targets (top 11)

geneUniProtsupporting neighboursconfidence
▸ USP2 O75604 1/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ CYP1A2 P05177 1/20 0.41
▸ ACACB O00763 2/20 0.41
▸ L3MBTL3 Q96JM7 1/20 0.40
▸ L3MBTL1 Q9Y468 1/20 0.40
▸ HPGD P15428 1/20 0.40
▸ GPR119 Q8TDV5 5/20 0.40
▸ EPHX2 P34913 1/20 0.40
▸ CYP11B2 P19099 1/20 0.39
▸ GPR183 P32249 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL896891 0.98 USP2 (0.45) USP2SMN1; SMN2CYP1A2ACACBL3MBTL3
SCHEMBL617801 0.91 CYP11B2 (0.45) USP2SMN1; SMN2CYP1A2ACACBL3MBTL3
SCHEMBL30684021 0.91 CYP11B2 (0.45) USP2SMN1; SMN2CYP1A2ACACBL3MBTL3
SCHEMBL29427773 0.91 CYP11B2 (0.45) USP2SMN1; SMN2CYP1A2ACACBL3MBTL3
SCHEMBL485160 0.91 USP2 (0.44) USP2SMN1; SMN2ACACBHPGDGPR119
SCHEMBL118654 0.90 CYP1A2 (0.50) USP2SMN1; SMN2CYP1A2ACACBGPR119
Hydrochloric Acid SCHEMBL15378006 0.90 USP2 (0.43) USP2SMN1; SMN2ACACBHPGDGPR119
Hydrochloric Acid SCHEMBL993329 0.90 TSHR (0.44) USP2SMN1; SMN2CYP1A2ACACBL3MBTL3
Trifluoromethanesulfonic Acid SCHEMBL29901719 0.89 GPR119 (0.39) USP2SMN1; SMN2ACACBGPR119
Hydrochloric Acid SCHEMBL2075849 0.89 CYP1A2 (0.49) USP2SMN1; SMN2CYP1A2ACACBGPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 463 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113121537-B Synthesis method of 2, 8-diazaspiro [4.5] decane-8-tert-butyl formate 南通药明康德医药科技有限公司 2022-11-08 — — CN claimed
EP-2569304-A1 SUBSTITUTED N-HETEROARYL SPIROLACTAM BIPYRROLIDINES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI (FR) 2013-03-20 — — EP claimed
WO-2011143148-A1 SUBSTITUTED N-HETEROARYL SPIROLACTAM BIPYRROLIDINES, PREPARATION AND THERAPEUTIC USE THEREOF SANOFI (FR) 2011-11-17 — — WO claimed
EP-2373652-A1 SUBSTITUTED PIPERIDINE SPIRO PYRROLIDINONE AND PIPERIDINONES USED AS H3 MODULATORS SANOFI (FR) 2011-10-12 — — EP claimed
WO-2010065803-A1 SUBSTITUTED PIPERIDINE SPIRO PYRROLIDINONE AND PIPERIDINONES USED AS H3 MODULATORS SANOFI-AVENTIS (FR) 2010-06-10 — — WO claimed
US-20260124309-A1 STAT6 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2026-05-07 — — US disclosed
US-20260125400-A1 TYK2 DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS INC (US) 2026-05-07 — — US disclosed
EP-4705293-A1 SPIRO-HETEROCYCLIC INHIBITORS OF KRAS G12C MUTANT PROTEINS AND USES THEREOF Amgen Inc. (US) 2026-03-11 — — EP disclosed
US-12558428-B2 Heterobifunctional compounds and their use in treating disease HALDA THERAPEUTICS OPCO, INC. (US) 2026-02-24 — — US disclosed
EP-3891149-B1 RET INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF SUNSHINE LAKE PHARMA CO LTD (CN) 2026-01-28 — — EP disclosed
EP-4674484-A2 THIENOPYRROLE COMPOUNDS Gilead Sciences, Inc. (US) 2026-01-07 — — EP disclosed
US-20250367129-A1 Lipid Compounds and Uses Thereof PFIZER (US) 2025-12-04 — — US disclosed
WO-2007030061-A1 NOVEL DIAZASPIROALKANES AND THEIR USE FOR TREATMENT OF CCR8 MEDIATED DISEASES ASTRAZENECA AB (SE) 2007-03-15 — — WO disclosed
WO-2007027734-A2 BICYCLIC AND BRIDGED NITROGEN HETEROCYCLES CHEMOCENTRYX, INC. (US) 2007-03-08 — — WO disclosed
WO-2006012470-A1 RIFAMYCIN DERIVATIVES FOR TREATING MICROBIAL INFECTIONS CUMBRE PHARMACEUTICALS INC. (US) 2006-02-02 — — WO disclosed
US-20060019985-A1 Rifamycin derivatives CUMBRE INC. (US) 2006-01-26 — — US disclosed
EP-1296921-A1 CYCLIC KETONES, THEIR PREPARATION AND THEIR USE IN THE SYNTHESIS OF AMINO ACIDS WARNER-LAMBERT COMPANY (US) 2003-04-02 — — EP disclosed
WO-2002000584-A1 CYCLIC KETONES, THEIR PREPARATION AND THEIR USE IN THE SYNTHESIS OF AMINO ACIDS WARNER-LAMBERT COMPANY (US) 2002-01-03 — — WO disclosed
EP-1061076-A1 N-ACYL CYCLIC AMINE DERIVATIVES BANYU PHARMACEUTICAL CO., LTD. (JP) 2000-12-20 — — EP disclosed
US-6140333-A FOR TREATMENT AND/OR PROPHYLAXIS OF DISEASES INCLUDE SUCH RESPIRATORY DISEASES AS CHRONIC OBSTRUCTIVE PULMONARY DISEASES, CHRONIC BRONCHITIS, ASTHMA, CHRONIC RESPIRATORY OBSTRUCTION, PULMONARY FIBROSIS, PULMONARY EMPHYSEMA BANYU PHARMACEUTICAL CO LTD (JP) 2000-10-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060019985-A1 Rifamycin derivatives RIF1, NQO1, MRM1 USP2 4422/4885SMN1; SMN2 3758/4885CYP1A2 698/4885
US-20260125400-A1 TYK2 DEGRADERS AND USES THEREOF TYK2, CSNK2A1, CSNK2A2 USP2 1713/4885SMN1; SMN2 1897/4885CYP1A2 632/4885
US-20260124309-A1 STAT6 DEGRADERS AND USES THEREOF STAT6, NCOR2, NCOR1 USP2 2189/4885SMN1; SMN2 2865/4885CYP1A2 780/4885
US-12558428-B2 Heterobifunctional compounds and their use in treating disease BRCA1, H1-0, FOXM1 USP2 4440/4885SMN1; SMN2 791/4885CYP1A2 277/4885
US-20250367129-A1 Lipid Compounds and Uses Thereof POLN, PHOSPHO1, NPC1 USP2 3149/4885SMN1; SMN2 552/4885CYP1A2 2520/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.